Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung disease, fatigue and seizures. Treatment includes enzyme replacement therapy.
Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gaucher Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gaucher Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 5 molecules, respectively.
Gaucher Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/gaucher-disease-pipeline-review-h2-2016
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gaucher Disease (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Gaucher Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gaucher Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gaucher Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gaucher Disease (Genetic Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001530739/sample
Reasons to buy:
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gaucher Disease (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gaucher Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001530739/discount
List of Content:
List of Tables 5
List of Figures 6
Report Coverage 7
Gaucher Disease Overview 8
Therapeutics Development 9
Pipeline Products for Gaucher Disease - Overview 9
Pipeline Products for Gaucher Disease - Comparative Analysis 10
Gaucher Disease - Therapeutics under Development by Companies 11
Gaucher Disease - Therapeutics under Investigation by Universities/Institutes 12
Gaucher Disease - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Gaucher Disease - Products under Development by Companies 15
Gaucher Disease - Products under Investigation by Universities/Institutes 16
Gaucher Disease - Companies Involved in Therapeutics Development 17
Actelion Ltd 17
Genzyme Corp 18
greenovation Biotech GmbH 19
JCR Pharmaceuticals Co Ltd 20
Lixte Biotechnology Holdings Inc 21
Lysosomal Therapeutics Inc 22
Neuraltus Pharmaceuticals Inc 23
Pharming Group NV 24
Protalix BioTherapeutics Inc 25
Sangamo BioSciences Inc 26
Shire Plc 27
The International Biotechnology Center (IBC) Generium 28
Gaucher Disease - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Key Companies profiles
greenovation Biotech GmbH
JCR Pharmaceuticals Co Ltd
Lixte Biotechnology Holdings Inc
Lysosomal Therapeutics Inc
Neuraltus Pharmaceuticals Inc
Pharming Group NV
Protalix BioTherapeutics Inc
Sangamo BioSciences Inc
The International Biotechnology Center (IBC) Generium
Email: [email protected]